nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—CYP2E1—lung cancer	0.218	0.656	CbGaD
Citalopram—ABCB1—lung cancer	0.114	0.344	CbGaD
Citalopram—CYP2C19—Gefitinib—lung cancer	0.021	0.055	CbGbCtD
Citalopram—CYP2C19—Teniposide—lung cancer	0.0204	0.0534	CbGbCtD
Citalopram—ABCB1—Topotecan—lung cancer	0.0185	0.0486	CbGbCtD
Citalopram—CYP2B6—Irinotecan—lung cancer	0.0176	0.0463	CbGbCtD
Citalopram—ABCB1—Gefitinib—lung cancer	0.0169	0.0444	CbGbCtD
Citalopram—CYP2D6—Gefitinib—lung cancer	0.016	0.0418	CbGbCtD
Citalopram—CYP2B6—Cisplatin—lung cancer	0.0144	0.0377	CbGbCtD
Citalopram—CYP2E1—Etoposide—lung cancer	0.0143	0.0376	CbGbCtD
Citalopram—ABCB1—Vinorelbine—lung cancer	0.013	0.0342	CbGbCtD
Citalopram—CYP2D6—Vinorelbine—lung cancer	0.0123	0.0322	CbGbCtD
Citalopram—CYP1A2—Erlotinib—lung cancer	0.0115	0.03	CbGbCtD
Citalopram—CYP3A4—Topotecan—lung cancer	0.0111	0.0291	CbGbCtD
Citalopram—ABCB1—Crizotinib—lung cancer	0.0104	0.0272	CbGbCtD
Citalopram—CYP3A4—Gefitinib—lung cancer	0.0101	0.0266	CbGbCtD
Citalopram—ABCB1—Gemcitabine—lung cancer	0.0101	0.0266	CbGbCtD
Citalopram—ABCB1—Erlotinib—lung cancer	0.01	0.0263	CbGbCtD
Citalopram—CYP3A4—Teniposide—lung cancer	0.00984	0.0258	CbGbCtD
Citalopram—CYP2B6—Doxorubicin—lung cancer	0.00964	0.0253	CbGbCtD
Citalopram—CYP2D6—Erlotinib—lung cancer	0.00944	0.0247	CbGbCtD
Citalopram—ABCB1—Paclitaxel—lung cancer	0.00917	0.024	CbGbCtD
Citalopram—ABCB1—Irinotecan—lung cancer	0.00904	0.0237	CbGbCtD
Citalopram—CYP1A2—Etoposide—lung cancer	0.00828	0.0217	CbGbCtD
Citalopram—ABCB1—Vinblastine—lung cancer	0.00804	0.0211	CbGbCtD
Citalopram—CYP3A4—Vinorelbine—lung cancer	0.00782	0.0205	CbGbCtD
Citalopram—CYP2D6—Vinblastine—lung cancer	0.00758	0.0199	CbGbCtD
Citalopram—ABCB1—Cisplatin—lung cancer	0.00737	0.0193	CbGbCtD
Citalopram—ABCB1—Etoposide—lung cancer	0.00724	0.019	CbGbCtD
Citalopram—ABCB1—Docetaxel—lung cancer	0.00663	0.0174	CbGbCtD
Citalopram—CYP3A4—Crizotinib—lung cancer	0.00622	0.0163	CbGbCtD
Citalopram—CYP3A4—Erlotinib—lung cancer	0.006	0.0157	CbGbCtD
Citalopram—CYP3A4—Paclitaxel—lung cancer	0.00549	0.0144	CbGbCtD
Citalopram—CYP3A4—Irinotecan—lung cancer	0.00542	0.0142	CbGbCtD
Citalopram—ABCB1—Doxorubicin—lung cancer	0.00494	0.013	CbGbCtD
Citalopram—CYP3A4—Vinblastine—lung cancer	0.00482	0.0126	CbGbCtD
Citalopram—ABCB1—Methotrexate—lung cancer	0.00479	0.0125	CbGbCtD
Citalopram—CYP2D6—Doxorubicin—lung cancer	0.00466	0.0122	CbGbCtD
Citalopram—CYP3A4—Etoposide—lung cancer	0.00434	0.0114	CbGbCtD
Citalopram—CYP3A4—Docetaxel—lung cancer	0.00397	0.0104	CbGbCtD
Citalopram—CYP3A4—Doxorubicin—lung cancer	0.00296	0.00776	CbGbCtD
Citalopram—Feeling abnormal—Etoposide—lung cancer	3.34e-05	0.000165	CcSEcCtD
Citalopram—Hyperglycaemia—Doxorubicin—lung cancer	3.34e-05	0.000165	CcSEcCtD
Citalopram—Diarrhoea—Irinotecan—lung cancer	3.34e-05	0.000164	CcSEcCtD
Citalopram—Pneumonia—Doxorubicin—lung cancer	3.32e-05	0.000164	CcSEcCtD
Citalopram—Gastrointestinal pain—Etoposide—lung cancer	3.32e-05	0.000164	CcSEcCtD
Citalopram—Shock—Docetaxel—lung cancer	3.32e-05	0.000163	CcSEcCtD
Citalopram—Nervous system disorder—Docetaxel—lung cancer	3.3e-05	0.000163	CcSEcCtD
Citalopram—Thrombocytopenia—Docetaxel—lung cancer	3.3e-05	0.000163	CcSEcCtD
Citalopram—Infestation NOS—Doxorubicin—lung cancer	3.3e-05	0.000163	CcSEcCtD
Citalopram—Infestation—Doxorubicin—lung cancer	3.3e-05	0.000163	CcSEcCtD
Citalopram—Visual impairment—Methotrexate—lung cancer	3.29e-05	0.000162	CcSEcCtD
Citalopram—Tachycardia—Docetaxel—lung cancer	3.29e-05	0.000162	CcSEcCtD
Citalopram—Feeling abnormal—Paclitaxel—lung cancer	3.28e-05	0.000162	CcSEcCtD
Citalopram—Skin disorder—Docetaxel—lung cancer	3.27e-05	0.000161	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Doxorubicin—lung cancer	3.27e-05	0.000161	CcSEcCtD
Citalopram—Hypersensitivity—Cisplatin—lung cancer	3.26e-05	0.000161	CcSEcCtD
Citalopram—Gastrointestinal pain—Paclitaxel—lung cancer	3.25e-05	0.00016	CcSEcCtD
Citalopram—Diarrhoea—Gemcitabine—lung cancer	3.25e-05	0.00016	CcSEcCtD
Citalopram—Erythema multiforme—Methotrexate—lung cancer	3.23e-05	0.000159	CcSEcCtD
Citalopram—Neuropathy peripheral—Doxorubicin—lung cancer	3.23e-05	0.000159	CcSEcCtD
Citalopram—Dizziness—Irinotecan—lung cancer	3.22e-05	0.000159	CcSEcCtD
Citalopram—Urticaria—Etoposide—lung cancer	3.22e-05	0.000159	CcSEcCtD
Citalopram—Stomatitis—Doxorubicin—lung cancer	3.21e-05	0.000159	CcSEcCtD
Citalopram—Jaundice—Doxorubicin—lung cancer	3.21e-05	0.000159	CcSEcCtD
Citalopram—Anorexia—Docetaxel—lung cancer	3.21e-05	0.000158	CcSEcCtD
Citalopram—Body temperature increased—Etoposide—lung cancer	3.21e-05	0.000158	CcSEcCtD
Citalopram—Abdominal pain—Etoposide—lung cancer	3.21e-05	0.000158	CcSEcCtD
Citalopram—Conjunctivitis—Doxorubicin—lung cancer	3.21e-05	0.000158	CcSEcCtD
Citalopram—Urinary tract infection—Doxorubicin—lung cancer	3.21e-05	0.000158	CcSEcCtD
Citalopram—Eye disorder—Methotrexate—lung cancer	3.2e-05	0.000158	CcSEcCtD
Citalopram—Tinnitus—Methotrexate—lung cancer	3.19e-05	0.000157	CcSEcCtD
Citalopram—Asthenia—Cisplatin—lung cancer	3.18e-05	0.000157	CcSEcCtD
Citalopram—Cardiac disorder—Methotrexate—lung cancer	3.17e-05	0.000156	CcSEcCtD
Citalopram—Sweating—Doxorubicin—lung cancer	3.16e-05	0.000156	CcSEcCtD
Citalopram—Urticaria—Paclitaxel—lung cancer	3.16e-05	0.000156	CcSEcCtD
Citalopram—Hypotension—Docetaxel—lung cancer	3.15e-05	0.000155	CcSEcCtD
Citalopram—Haematuria—Doxorubicin—lung cancer	3.14e-05	0.000155	CcSEcCtD
Citalopram—Abdominal pain—Paclitaxel—lung cancer	3.14e-05	0.000155	CcSEcCtD
Citalopram—Body temperature increased—Paclitaxel—lung cancer	3.14e-05	0.000155	CcSEcCtD
Citalopram—Hepatobiliary disease—Doxorubicin—lung cancer	3.12e-05	0.000154	CcSEcCtD
Citalopram—Epistaxis—Doxorubicin—lung cancer	3.11e-05	0.000153	CcSEcCtD
Citalopram—Angiopathy—Methotrexate—lung cancer	3.1e-05	0.000153	CcSEcCtD
Citalopram—Vomiting—Irinotecan—lung cancer	3.1e-05	0.000153	CcSEcCtD
Citalopram—Sinusitis—Doxorubicin—lung cancer	3.09e-05	0.000153	CcSEcCtD
Citalopram—Immune system disorder—Methotrexate—lung cancer	3.09e-05	0.000152	CcSEcCtD
Citalopram—Mediastinal disorder—Methotrexate—lung cancer	3.08e-05	0.000152	CcSEcCtD
Citalopram—Agranulocytosis—Doxorubicin—lung cancer	3.08e-05	0.000152	CcSEcCtD
Citalopram—Rash—Irinotecan—lung cancer	3.07e-05	0.000152	CcSEcCtD
Citalopram—Dermatitis—Irinotecan—lung cancer	3.07e-05	0.000151	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Docetaxel—lung cancer	3.07e-05	0.000151	CcSEcCtD
Citalopram—Chills—Methotrexate—lung cancer	3.07e-05	0.000151	CcSEcCtD
Citalopram—Headache—Irinotecan—lung cancer	3.05e-05	0.000151	CcSEcCtD
Citalopram—Insomnia—Docetaxel—lung cancer	3.05e-05	0.00015	CcSEcCtD
Citalopram—Diarrhoea—Cisplatin—lung cancer	3.03e-05	0.000149	CcSEcCtD
Citalopram—Paraesthesia—Docetaxel—lung cancer	3.03e-05	0.000149	CcSEcCtD
Citalopram—Alopecia—Methotrexate—lung cancer	3.02e-05	0.000149	CcSEcCtD
Citalopram—Vomiting—Gemcitabine—lung cancer	3.02e-05	0.000149	CcSEcCtD
Citalopram—Bradycardia—Doxorubicin—lung cancer	3.01e-05	0.000149	CcSEcCtD
Citalopram—Dyspnoea—Docetaxel—lung cancer	3e-05	0.000148	CcSEcCtD
Citalopram—Somnolence—Docetaxel—lung cancer	3e-05	0.000148	CcSEcCtD
Citalopram—Mental disorder—Methotrexate—lung cancer	3e-05	0.000148	CcSEcCtD
Citalopram—Rash—Gemcitabine—lung cancer	2.99e-05	0.000148	CcSEcCtD
Citalopram—Dermatitis—Gemcitabine—lung cancer	2.99e-05	0.000148	CcSEcCtD
Citalopram—Hypersensitivity—Etoposide—lung cancer	2.99e-05	0.000147	CcSEcCtD
Citalopram—Erythema—Methotrexate—lung cancer	2.98e-05	0.000147	CcSEcCtD
Citalopram—Malnutrition—Methotrexate—lung cancer	2.98e-05	0.000147	CcSEcCtD
Citalopram—Haemoglobin—Doxorubicin—lung cancer	2.98e-05	0.000147	CcSEcCtD
Citalopram—Headache—Gemcitabine—lung cancer	2.98e-05	0.000147	CcSEcCtD
Citalopram—Rhinitis—Doxorubicin—lung cancer	2.97e-05	0.000146	CcSEcCtD
Citalopram—Dyspepsia—Docetaxel—lung cancer	2.97e-05	0.000146	CcSEcCtD
Citalopram—Haemorrhage—Doxorubicin—lung cancer	2.96e-05	0.000146	CcSEcCtD
Citalopram—Hepatitis—Doxorubicin—lung cancer	2.96e-05	0.000146	CcSEcCtD
Citalopram—Hypoaesthesia—Doxorubicin—lung cancer	2.95e-05	0.000145	CcSEcCtD
Citalopram—Pharyngitis—Doxorubicin—lung cancer	2.94e-05	0.000145	CcSEcCtD
Citalopram—Decreased appetite—Docetaxel—lung cancer	2.93e-05	0.000144	CcSEcCtD
Citalopram—Hypersensitivity—Paclitaxel—lung cancer	2.93e-05	0.000144	CcSEcCtD
Citalopram—Urinary tract disorder—Doxorubicin—lung cancer	2.92e-05	0.000144	CcSEcCtD
Citalopram—Oedema peripheral—Doxorubicin—lung cancer	2.92e-05	0.000144	CcSEcCtD
Citalopram—Dysgeusia—Methotrexate—lung cancer	2.91e-05	0.000144	CcSEcCtD
Citalopram—Gastrointestinal disorder—Docetaxel—lung cancer	2.91e-05	0.000143	CcSEcCtD
Citalopram—Asthenia—Etoposide—lung cancer	2.91e-05	0.000143	CcSEcCtD
Citalopram—Connective tissue disorder—Doxorubicin—lung cancer	2.91e-05	0.000143	CcSEcCtD
Citalopram—Fatigue—Docetaxel—lung cancer	2.91e-05	0.000143	CcSEcCtD
Citalopram—Urethral disorder—Doxorubicin—lung cancer	2.9e-05	0.000143	CcSEcCtD
Citalopram—Nausea—Irinotecan—lung cancer	2.9e-05	0.000143	CcSEcCtD
Citalopram—Constipation—Docetaxel—lung cancer	2.88e-05	0.000142	CcSEcCtD
Citalopram—Pain—Docetaxel—lung cancer	2.88e-05	0.000142	CcSEcCtD
Citalopram—Back pain—Methotrexate—lung cancer	2.88e-05	0.000142	CcSEcCtD
Citalopram—Pruritus—Etoposide—lung cancer	2.87e-05	0.000141	CcSEcCtD
Citalopram—Visual impairment—Doxorubicin—lung cancer	2.85e-05	0.000141	CcSEcCtD
Citalopram—Asthenia—Paclitaxel—lung cancer	2.85e-05	0.000141	CcSEcCtD
Citalopram—Nausea—Gemcitabine—lung cancer	2.82e-05	0.000139	CcSEcCtD
Citalopram—Vomiting—Cisplatin—lung cancer	2.81e-05	0.000139	CcSEcCtD
Citalopram—Pruritus—Paclitaxel—lung cancer	2.81e-05	0.000139	CcSEcCtD
Citalopram—Vision blurred—Methotrexate—lung cancer	2.8e-05	0.000138	CcSEcCtD
Citalopram—Erythema multiforme—Doxorubicin—lung cancer	2.8e-05	0.000138	CcSEcCtD
Citalopram—Rash—Cisplatin—lung cancer	2.79e-05	0.000138	CcSEcCtD
Citalopram—Dermatitis—Cisplatin—lung cancer	2.79e-05	0.000137	CcSEcCtD
Citalopram—Feeling abnormal—Docetaxel—lung cancer	2.78e-05	0.000137	CcSEcCtD
Citalopram—Diarrhoea—Etoposide—lung cancer	2.77e-05	0.000137	CcSEcCtD
Citalopram—Eye disorder—Doxorubicin—lung cancer	2.77e-05	0.000136	CcSEcCtD
Citalopram—Ill-defined disorder—Methotrexate—lung cancer	2.76e-05	0.000136	CcSEcCtD
Citalopram—Tinnitus—Doxorubicin—lung cancer	2.76e-05	0.000136	CcSEcCtD
Citalopram—Gastrointestinal pain—Docetaxel—lung cancer	2.76e-05	0.000136	CcSEcCtD
Citalopram—Anaemia—Methotrexate—lung cancer	2.75e-05	0.000136	CcSEcCtD
Citalopram—Flushing—Doxorubicin—lung cancer	2.75e-05	0.000135	CcSEcCtD
Citalopram—Cardiac disorder—Doxorubicin—lung cancer	2.75e-05	0.000135	CcSEcCtD
Citalopram—Diarrhoea—Paclitaxel—lung cancer	2.72e-05	0.000134	CcSEcCtD
Citalopram—Angiopathy—Doxorubicin—lung cancer	2.69e-05	0.000132	CcSEcCtD
Citalopram—Malaise—Methotrexate—lung cancer	2.68e-05	0.000132	CcSEcCtD
Citalopram—Dizziness—Etoposide—lung cancer	2.68e-05	0.000132	CcSEcCtD
Citalopram—Immune system disorder—Doxorubicin—lung cancer	2.67e-05	0.000132	CcSEcCtD
Citalopram—Vertigo—Methotrexate—lung cancer	2.67e-05	0.000132	CcSEcCtD
Citalopram—Mediastinal disorder—Doxorubicin—lung cancer	2.67e-05	0.000132	CcSEcCtD
Citalopram—Abdominal pain—Docetaxel—lung cancer	2.66e-05	0.000131	CcSEcCtD
Citalopram—Body temperature increased—Docetaxel—lung cancer	2.66e-05	0.000131	CcSEcCtD
Citalopram—Leukopenia—Methotrexate—lung cancer	2.66e-05	0.000131	CcSEcCtD
Citalopram—Chills—Doxorubicin—lung cancer	2.66e-05	0.000131	CcSEcCtD
Citalopram—Arrhythmia—Doxorubicin—lung cancer	2.64e-05	0.00013	CcSEcCtD
Citalopram—Dizziness—Paclitaxel—lung cancer	2.63e-05	0.00013	CcSEcCtD
Citalopram—Nausea—Cisplatin—lung cancer	2.63e-05	0.00013	CcSEcCtD
Citalopram—Alopecia—Doxorubicin—lung cancer	2.62e-05	0.000129	CcSEcCtD
Citalopram—Cough—Methotrexate—lung cancer	2.6e-05	0.000128	CcSEcCtD
Citalopram—Mental disorder—Doxorubicin—lung cancer	2.59e-05	0.000128	CcSEcCtD
Citalopram—Convulsion—Methotrexate—lung cancer	2.58e-05	0.000127	CcSEcCtD
Citalopram—Vomiting—Etoposide—lung cancer	2.58e-05	0.000127	CcSEcCtD
Citalopram—Malnutrition—Doxorubicin—lung cancer	2.58e-05	0.000127	CcSEcCtD
Citalopram—Erythema—Doxorubicin—lung cancer	2.58e-05	0.000127	CcSEcCtD
Citalopram—Rash—Etoposide—lung cancer	2.56e-05	0.000126	CcSEcCtD
Citalopram—Dermatitis—Etoposide—lung cancer	2.55e-05	0.000126	CcSEcCtD
Citalopram—Headache—Etoposide—lung cancer	2.54e-05	0.000125	CcSEcCtD
Citalopram—Flatulence—Doxorubicin—lung cancer	2.54e-05	0.000125	CcSEcCtD
Citalopram—Myalgia—Methotrexate—lung cancer	2.53e-05	0.000125	CcSEcCtD
Citalopram—Chest pain—Methotrexate—lung cancer	2.53e-05	0.000125	CcSEcCtD
Citalopram—Arthralgia—Methotrexate—lung cancer	2.53e-05	0.000125	CcSEcCtD
Citalopram—Tension—Doxorubicin—lung cancer	2.53e-05	0.000125	CcSEcCtD
Citalopram—Vomiting—Paclitaxel—lung cancer	2.53e-05	0.000125	CcSEcCtD
Citalopram—Dysgeusia—Doxorubicin—lung cancer	2.52e-05	0.000124	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	2.52e-05	0.000124	CcSEcCtD
Citalopram—Rash—Paclitaxel—lung cancer	2.51e-05	0.000124	CcSEcCtD
Citalopram—Dermatitis—Paclitaxel—lung cancer	2.5e-05	0.000124	CcSEcCtD
Citalopram—Discomfort—Methotrexate—lung cancer	2.5e-05	0.000123	CcSEcCtD
Citalopram—Nervousness—Doxorubicin—lung cancer	2.5e-05	0.000123	CcSEcCtD
Citalopram—Back pain—Doxorubicin—lung cancer	2.49e-05	0.000123	CcSEcCtD
Citalopram—Headache—Paclitaxel—lung cancer	2.49e-05	0.000123	CcSEcCtD
Citalopram—Hypersensitivity—Docetaxel—lung cancer	2.48e-05	0.000122	CcSEcCtD
Citalopram—Muscle spasms—Doxorubicin—lung cancer	2.48e-05	0.000122	CcSEcCtD
Citalopram—Confusional state—Methotrexate—lung cancer	2.45e-05	0.000121	CcSEcCtD
Citalopram—Anaphylactic shock—Methotrexate—lung cancer	2.43e-05	0.00012	CcSEcCtD
Citalopram—Vision blurred—Doxorubicin—lung cancer	2.43e-05	0.00012	CcSEcCtD
Citalopram—Asthenia—Docetaxel—lung cancer	2.42e-05	0.000119	CcSEcCtD
Citalopram—Infection—Methotrexate—lung cancer	2.41e-05	0.000119	CcSEcCtD
Citalopram—Nausea—Etoposide—lung cancer	2.41e-05	0.000119	CcSEcCtD
Citalopram—Ill-defined disorder—Doxorubicin—lung cancer	2.39e-05	0.000118	CcSEcCtD
Citalopram—Pruritus—Docetaxel—lung cancer	2.38e-05	0.000118	CcSEcCtD
Citalopram—Nervous system disorder—Methotrexate—lung cancer	2.38e-05	0.000117	CcSEcCtD
Citalopram—Anaemia—Doxorubicin—lung cancer	2.38e-05	0.000117	CcSEcCtD
Citalopram—Thrombocytopenia—Methotrexate—lung cancer	2.38e-05	0.000117	CcSEcCtD
Citalopram—Agitation—Doxorubicin—lung cancer	2.37e-05	0.000117	CcSEcCtD
Citalopram—Nausea—Paclitaxel—lung cancer	2.36e-05	0.000116	CcSEcCtD
Citalopram—Skin disorder—Methotrexate—lung cancer	2.36e-05	0.000116	CcSEcCtD
Citalopram—Hyperhidrosis—Methotrexate—lung cancer	2.35e-05	0.000116	CcSEcCtD
Citalopram—Malaise—Doxorubicin—lung cancer	2.32e-05	0.000115	CcSEcCtD
Citalopram—Vertigo—Doxorubicin—lung cancer	2.32e-05	0.000114	CcSEcCtD
Citalopram—Anorexia—Methotrexate—lung cancer	2.32e-05	0.000114	CcSEcCtD
Citalopram—Syncope—Doxorubicin—lung cancer	2.31e-05	0.000114	CcSEcCtD
Citalopram—Leukopenia—Doxorubicin—lung cancer	2.31e-05	0.000114	CcSEcCtD
Citalopram—Diarrhoea—Docetaxel—lung cancer	2.31e-05	0.000114	CcSEcCtD
Citalopram—Palpitations—Doxorubicin—lung cancer	2.28e-05	0.000112	CcSEcCtD
Citalopram—Hypotension—Methotrexate—lung cancer	2.27e-05	0.000112	CcSEcCtD
Citalopram—Loss of consciousness—Doxorubicin—lung cancer	2.27e-05	0.000112	CcSEcCtD
Citalopram—Cough—Doxorubicin—lung cancer	2.25e-05	0.000111	CcSEcCtD
Citalopram—Convulsion—Doxorubicin—lung cancer	2.23e-05	0.00011	CcSEcCtD
Citalopram—Dizziness—Docetaxel—lung cancer	2.23e-05	0.00011	CcSEcCtD
Citalopram—Hypertension—Doxorubicin—lung cancer	2.22e-05	0.00011	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Methotrexate—lung cancer	2.21e-05	0.000109	CcSEcCtD
Citalopram—Insomnia—Methotrexate—lung cancer	2.2e-05	0.000108	CcSEcCtD
Citalopram—Chest pain—Doxorubicin—lung cancer	2.19e-05	0.000108	CcSEcCtD
Citalopram—Arthralgia—Doxorubicin—lung cancer	2.19e-05	0.000108	CcSEcCtD
Citalopram—Myalgia—Doxorubicin—lung cancer	2.19e-05	0.000108	CcSEcCtD
Citalopram—Anxiety—Doxorubicin—lung cancer	2.19e-05	0.000108	CcSEcCtD
Citalopram—Paraesthesia—Methotrexate—lung cancer	2.18e-05	0.000108	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.18e-05	0.000107	CcSEcCtD
Citalopram—Discomfort—Doxorubicin—lung cancer	2.17e-05	0.000107	CcSEcCtD
Citalopram—Dyspnoea—Methotrexate—lung cancer	2.17e-05	0.000107	CcSEcCtD
Citalopram—Somnolence—Methotrexate—lung cancer	2.16e-05	0.000106	CcSEcCtD
Citalopram—Dry mouth—Doxorubicin—lung cancer	2.15e-05	0.000106	CcSEcCtD
Citalopram—Vomiting—Docetaxel—lung cancer	2.14e-05	0.000106	CcSEcCtD
Citalopram—Dyspepsia—Methotrexate—lung cancer	2.14e-05	0.000105	CcSEcCtD
Citalopram—Rash—Docetaxel—lung cancer	2.12e-05	0.000105	CcSEcCtD
Citalopram—Dermatitis—Docetaxel—lung cancer	2.12e-05	0.000105	CcSEcCtD
Citalopram—Confusional state—Doxorubicin—lung cancer	2.12e-05	0.000105	CcSEcCtD
Citalopram—Decreased appetite—Methotrexate—lung cancer	2.11e-05	0.000104	CcSEcCtD
Citalopram—Headache—Docetaxel—lung cancer	2.11e-05	0.000104	CcSEcCtD
Citalopram—Oedema—Doxorubicin—lung cancer	2.1e-05	0.000104	CcSEcCtD
Citalopram—Anaphylactic shock—Doxorubicin—lung cancer	2.1e-05	0.000104	CcSEcCtD
Citalopram—Gastrointestinal disorder—Methotrexate—lung cancer	2.1e-05	0.000103	CcSEcCtD
Citalopram—Fatigue—Methotrexate—lung cancer	2.09e-05	0.000103	CcSEcCtD
Citalopram—Infection—Doxorubicin—lung cancer	2.09e-05	0.000103	CcSEcCtD
Citalopram—Pain—Methotrexate—lung cancer	2.08e-05	0.000102	CcSEcCtD
Citalopram—Shock—Doxorubicin—lung cancer	2.07e-05	0.000102	CcSEcCtD
Citalopram—Nervous system disorder—Doxorubicin—lung cancer	2.06e-05	0.000102	CcSEcCtD
Citalopram—Thrombocytopenia—Doxorubicin—lung cancer	2.06e-05	0.000102	CcSEcCtD
Citalopram—Tachycardia—Doxorubicin—lung cancer	2.05e-05	0.000101	CcSEcCtD
Citalopram—Skin disorder—Doxorubicin—lung cancer	2.04e-05	0.000101	CcSEcCtD
Citalopram—Hyperhidrosis—Doxorubicin—lung cancer	2.03e-05	0.0001	CcSEcCtD
Citalopram—Anorexia—Doxorubicin—lung cancer	2e-05	9.89e-05	CcSEcCtD
Citalopram—Nausea—Docetaxel—lung cancer	2e-05	9.87e-05	CcSEcCtD
Citalopram—Feeling abnormal—Methotrexate—lung cancer	2e-05	9.87e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Methotrexate—lung cancer	1.99e-05	9.79e-05	CcSEcCtD
Citalopram—Hypotension—Doxorubicin—lung cancer	1.97e-05	9.69e-05	CcSEcCtD
Citalopram—Urticaria—Methotrexate—lung cancer	1.93e-05	9.51e-05	CcSEcCtD
Citalopram—Abdominal pain—Methotrexate—lung cancer	1.92e-05	9.47e-05	CcSEcCtD
Citalopram—Body temperature increased—Methotrexate—lung cancer	1.92e-05	9.47e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Doxorubicin—lung cancer	1.92e-05	9.45e-05	CcSEcCtD
Citalopram—Insomnia—Doxorubicin—lung cancer	1.9e-05	9.38e-05	CcSEcCtD
Citalopram—Paraesthesia—Doxorubicin—lung cancer	1.89e-05	9.31e-05	CcSEcCtD
Citalopram—Dyspnoea—Doxorubicin—lung cancer	1.88e-05	9.25e-05	CcSEcCtD
Citalopram—Somnolence—Doxorubicin—lung cancer	1.87e-05	9.22e-05	CcSEcCtD
Citalopram—Dyspepsia—Doxorubicin—lung cancer	1.85e-05	9.13e-05	CcSEcCtD
Citalopram—Decreased appetite—Doxorubicin—lung cancer	1.83e-05	9.02e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Doxorubicin—lung cancer	1.82e-05	8.95e-05	CcSEcCtD
Citalopram—Fatigue—Doxorubicin—lung cancer	1.81e-05	8.94e-05	CcSEcCtD
Citalopram—Constipation—Doxorubicin—lung cancer	1.8e-05	8.87e-05	CcSEcCtD
Citalopram—Pain—Doxorubicin—lung cancer	1.8e-05	8.87e-05	CcSEcCtD
Citalopram—Hypersensitivity—Methotrexate—lung cancer	1.79e-05	8.82e-05	CcSEcCtD
Citalopram—Asthenia—Methotrexate—lung cancer	1.74e-05	8.59e-05	CcSEcCtD
Citalopram—Feeling abnormal—Doxorubicin—lung cancer	1.73e-05	8.55e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Doxorubicin—lung cancer	1.72e-05	8.48e-05	CcSEcCtD
Citalopram—Pruritus—Methotrexate—lung cancer	1.72e-05	8.47e-05	CcSEcCtD
Citalopram—Urticaria—Doxorubicin—lung cancer	1.67e-05	8.24e-05	CcSEcCtD
Citalopram—Abdominal pain—Doxorubicin—lung cancer	1.66e-05	8.2e-05	CcSEcCtD
Citalopram—Body temperature increased—Doxorubicin—lung cancer	1.66e-05	8.2e-05	CcSEcCtD
Citalopram—Diarrhoea—Methotrexate—lung cancer	1.66e-05	8.19e-05	CcSEcCtD
Citalopram—Dizziness—Methotrexate—lung cancer	1.61e-05	7.92e-05	CcSEcCtD
Citalopram—Hypersensitivity—Doxorubicin—lung cancer	1.55e-05	7.64e-05	CcSEcCtD
Citalopram—Vomiting—Methotrexate—lung cancer	1.54e-05	7.62e-05	CcSEcCtD
Citalopram—Rash—Methotrexate—lung cancer	1.53e-05	7.55e-05	CcSEcCtD
Citalopram—Dermatitis—Methotrexate—lung cancer	1.53e-05	7.54e-05	CcSEcCtD
Citalopram—Headache—Methotrexate—lung cancer	1.52e-05	7.5e-05	CcSEcCtD
Citalopram—Asthenia—Doxorubicin—lung cancer	1.51e-05	7.44e-05	CcSEcCtD
Citalopram—Pruritus—Doxorubicin—lung cancer	1.49e-05	7.34e-05	CcSEcCtD
Citalopram—Nausea—Methotrexate—lung cancer	1.44e-05	7.11e-05	CcSEcCtD
Citalopram—Diarrhoea—Doxorubicin—lung cancer	1.44e-05	7.1e-05	CcSEcCtD
Citalopram—Dizziness—Doxorubicin—lung cancer	1.39e-05	6.86e-05	CcSEcCtD
Citalopram—Vomiting—Doxorubicin—lung cancer	1.34e-05	6.59e-05	CcSEcCtD
Citalopram—Rash—Doxorubicin—lung cancer	1.33e-05	6.54e-05	CcSEcCtD
Citalopram—Dermatitis—Doxorubicin—lung cancer	1.32e-05	6.53e-05	CcSEcCtD
Citalopram—Headache—Doxorubicin—lung cancer	1.32e-05	6.5e-05	CcSEcCtD
Citalopram—Nausea—Doxorubicin—lung cancer	1.25e-05	6.16e-05	CcSEcCtD
Citalopram—CYP2E1—Metabolism—CREBBP—lung cancer	3.85e-06	4.58e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CREBBP—lung cancer	3.84e-06	4.58e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL6R—lung cancer	3.84e-06	4.57e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CREBBP—lung cancer	3.83e-06	4.56e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—BRAF—lung cancer	3.82e-06	4.55e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ENO1—lung cancer	3.82e-06	4.54e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PIK3CA—lung cancer	3.78e-06	4.5e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL6R—lung cancer	3.78e-06	4.5e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—EGFR—lung cancer	3.78e-06	4.5e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CREBBP—lung cancer	3.77e-06	4.49e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MDM2—lung cancer	3.77e-06	4.49e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—EGFR—lung cancer	3.77e-06	4.48e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CYP1A1—lung cancer	3.76e-06	4.48e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—RAF1—lung cancer	3.76e-06	4.47e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ERCC2—lung cancer	3.73e-06	4.44e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CD—lung cancer	3.73e-06	4.44e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ERBB2—lung cancer	3.72e-06	4.42e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.71e-06	4.42e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—EGFR—lung cancer	3.71e-06	4.41e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—ALB—lung cancer	3.68e-06	4.38e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAP2K1—lung cancer	3.67e-06	4.37e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MTOR—lung cancer	3.67e-06	4.37e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CB—lung cancer	3.67e-06	4.37e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTP1—lung cancer	3.66e-06	4.35e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAP2K1—lung cancer	3.66e-06	4.35e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CD—lung cancer	3.65e-06	4.34e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CD—lung cancer	3.64e-06	4.34e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CD—lung cancer	3.63e-06	4.33e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—lung cancer	3.61e-06	4.3e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ALB—lung cancer	3.6e-06	4.29e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAP2K1—lung cancer	3.6e-06	4.29e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—lung cancer	3.6e-06	4.28e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CD—lung cancer	3.58e-06	4.26e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—KRAS—lung cancer	3.57e-06	4.25e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CAT—lung cancer	3.56e-06	4.24e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—KRAS—lung cancer	3.56e-06	4.23e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—lung cancer	3.54e-06	4.22e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.54e-06	4.21e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CXCL8—lung cancer	3.52e-06	4.19e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—APOA1—lung cancer	3.51e-06	4.18e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—KRAS—lung cancer	3.5e-06	4.17e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HRAS—lung cancer	3.5e-06	4.17e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ABCB1—lung cancer	3.46e-06	4.12e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—APOA1—lung cancer	3.42e-06	4.08e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP2E1—lung cancer	3.42e-06	4.07e-05	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—AKT1—lung cancer	3.4e-06	4.05e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—TYMS—lung cancer	3.4e-06	4.05e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NQO1—lung cancer	3.38e-06	4.03e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CASP3—lung cancer	3.37e-06	4.01e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL2—lung cancer	3.37e-06	4.01e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTM1—lung cancer	3.36e-06	4e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.36e-06	4e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL6—lung cancer	3.35e-06	3.99e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCND1—lung cancer	3.28e-06	3.91e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—lung cancer	3.28e-06	3.9e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—JUN—lung cancer	3.28e-06	3.9e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—lung cancer	3.27e-06	3.89e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MDM2—lung cancer	3.27e-06	3.89e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MDM2—lung cancer	3.25e-06	3.88e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—RAF1—lung cancer	3.25e-06	3.87e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CB—lung cancer	3.25e-06	3.87e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—RAF1—lung cancer	3.24e-06	3.86e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—APOA1—lung cancer	3.23e-06	3.84e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ERBB2—lung cancer	3.22e-06	3.83e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—lung cancer	3.22e-06	3.83e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—lung cancer	3.22e-06	3.83e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ERBB2—lung cancer	3.21e-06	3.82e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MDM2—lung cancer	3.2e-06	3.81e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CG—lung cancer	3.2e-06	3.81e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—RAF1—lung cancer	3.19e-06	3.8e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MMP9—lung cancer	3.19e-06	3.79e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP1A1—lung cancer	3.19e-06	3.79e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CB—lung cancer	3.18e-06	3.79e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CB—lung cancer	3.18e-06	3.78e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MTOR—lung cancer	3.18e-06	3.78e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1A—lung cancer	3.18e-06	3.78e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTEN—lung cancer	3.17e-06	3.77e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CB—lung cancer	3.17e-06	3.77e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MTOR—lung cancer	3.17e-06	3.77e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ERCC2—lung cancer	3.16e-06	3.76e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ERBB2—lung cancer	3.16e-06	3.76e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—lung cancer	3.15e-06	3.75e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CG—lung cancer	3.13e-06	3.72e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MTOR—lung cancer	3.12e-06	3.71e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CB—lung cancer	3.12e-06	3.71e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—AKT1—lung cancer	3.09e-06	3.68e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CXCL8—lung cancer	3.05e-06	3.63e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—STK11—lung cancer	3.05e-06	3.63e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—POMC—lung cancer	3.05e-06	3.63e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CXCL8—lung cancer	3.04e-06	3.62e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HRAS—lung cancer	3.03e-06	3.61e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HRAS—lung cancer	3.02e-06	3.6e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EP300—lung cancer	3.02e-06	3.6e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CXCL8—lung cancer	3e-06	3.57e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HRAS—lung cancer	2.98e-06	3.54e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—POMC—lung cancer	2.98e-06	3.54e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CREBBP—lung cancer	2.97e-06	3.54e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—AKT1—lung cancer	2.95e-06	3.51e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CG—lung cancer	2.95e-06	3.51e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—AKT1—lung cancer	2.94e-06	3.5e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SRC—lung cancer	2.94e-06	3.5e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CASP3—lung cancer	2.92e-06	3.48e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL2—lung cancer	2.92e-06	3.47e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CASP3—lung cancer	2.91e-06	3.47e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL2—lung cancer	2.91e-06	3.46e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL6—lung cancer	2.9e-06	3.46e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CREBBP—lung cancer	2.9e-06	3.45e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	2.89e-06	3.45e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL6—lung cancer	2.89e-06	3.45e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CASP3—lung cancer	2.87e-06	3.41e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL2—lung cancer	2.86e-06	3.41e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—lung cancer	2.86e-06	3.41e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL6—lung cancer	2.85e-06	3.39e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCND1—lung cancer	2.84e-06	3.39e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—JUN—lung cancer	2.84e-06	3.38e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCND1—lung cancer	2.84e-06	3.38e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT3—lung cancer	2.83e-06	3.37e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—JUN—lung cancer	2.83e-06	3.37e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NRAS—lung cancer	2.83e-06	3.37e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTP1—lung cancer	2.82e-06	3.36e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CD—lung cancer	2.82e-06	3.35e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTEN—lung cancer	2.81e-06	3.34e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—POMC—lung cancer	2.8e-06	3.34e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCND1—lung cancer	2.79e-06	3.32e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—JUN—lung cancer	2.79e-06	3.32e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ALB—lung cancer	2.78e-06	3.31e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MMP9—lung cancer	2.76e-06	3.29e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MMP9—lung cancer	2.75e-06	3.28e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1A—lung cancer	2.75e-06	3.28e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTEN—lung cancer	2.75e-06	3.27e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CD—lung cancer	2.75e-06	3.27e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CAT—lung cancer	2.75e-06	3.27e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTEN—lung cancer	2.75e-06	3.27e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1A—lung cancer	2.74e-06	3.27e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTEN—lung cancer	2.74e-06	3.26e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—APOA1—lung cancer	2.73e-06	3.25e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CREBBP—lung cancer	2.73e-06	3.25e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ALB—lung cancer	2.71e-06	3.23e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MMP9—lung cancer	2.71e-06	3.23e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK3—lung cancer	2.71e-06	3.22e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	2.7e-06	3.21e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTEN—lung cancer	2.69e-06	3.21e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—AKT1—lung cancer	2.68e-06	3.19e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—EP300—lung cancer	2.68e-06	3.19e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ABCB1—lung cancer	2.67e-06	3.18e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—AKT1—lung cancer	2.67e-06	3.18e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MYC—lung cancer	2.63e-06	3.13e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—AKT1—lung cancer	2.63e-06	3.13e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TYMS—lung cancer	2.62e-06	3.12e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—EP300—lung cancer	2.62e-06	3.12e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EP300—lung cancer	2.62e-06	3.12e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.62e-06	3.12e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EP300—lung cancer	2.61e-06	3.11e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTM1—lung cancer	2.59e-06	3.09e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CD—lung cancer	2.59e-06	3.08e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGFR—lung cancer	2.58e-06	3.07e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EP300—lung cancer	2.57e-06	3.06e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ALB—lung cancer	2.56e-06	3.04e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SRC—lung cancer	2.55e-06	3.03e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SRC—lung cancer	2.54e-06	3.02e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SRC—lung cancer	2.5e-06	2.97e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CG—lung cancer	2.5e-06	2.97e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—lung cancer	2.48e-06	2.95e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—lung cancer	2.47e-06	2.94e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP1A1—lung cancer	2.46e-06	2.93e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT3—lung cancer	2.46e-06	2.92e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CB—lung cancer	2.45e-06	2.92e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NRAS—lung cancer	2.45e-06	2.92e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT3—lung cancer	2.45e-06	2.91e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NRAS—lung cancer	2.44e-06	2.91e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ERCC2—lung cancer	2.44e-06	2.9e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—lung cancer	2.43e-06	2.9e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KRAS—lung cancer	2.43e-06	2.9e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—lung cancer	2.43e-06	2.9e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT3—lung cancer	2.41e-06	2.87e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NRAS—lung cancer	2.4e-06	2.86e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CB—lung cancer	2.4e-06	2.85e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—POMC—lung cancer	2.38e-06	2.83e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—lung cancer	2.37e-06	2.83e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK3—lung cancer	2.35e-06	2.79e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK3—lung cancer	2.34e-06	2.78e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CREBBP—lung cancer	2.31e-06	2.75e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK3—lung cancer	2.3e-06	2.74e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MYC—lung cancer	2.28e-06	2.72e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MYC—lung cancer	2.27e-06	2.71e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CB—lung cancer	2.26e-06	2.69e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MYC—lung cancer	2.24e-06	2.67e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—lung cancer	2.24e-06	2.66e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—lung cancer	2.24e-06	2.66e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGFR—lung cancer	2.23e-06	2.66e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGFR—lung cancer	2.22e-06	2.65e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CD—lung cancer	2.19e-06	2.61e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGFR—lung cancer	2.19e-06	2.61e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ALB—lung cancer	2.17e-06	2.58e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—lung cancer	2.16e-06	2.57e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTEN—lung cancer	2.12e-06	2.52e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—APOA1—lung cancer	2.11e-06	2.51e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KRAS—lung cancer	2.11e-06	2.51e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KRAS—lung cancer	2.1e-06	2.5e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTEN—lung cancer	2.07e-06	2.46e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KRAS—lung cancer	2.07e-06	2.46e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HRAS—lung cancer	2.07e-06	2.46e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—EP300—lung cancer	2.02e-06	2.41e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—lung cancer	1.98e-06	2.36e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL6—lung cancer	1.98e-06	2.36e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—EP300—lung cancer	1.97e-06	2.35e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTEN—lung cancer	1.95e-06	2.32e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—lung cancer	1.94e-06	2.31e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—lung cancer	1.94e-06	2.31e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—lung cancer	1.93e-06	2.3e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CG—lung cancer	1.93e-06	2.29e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CB—lung cancer	1.91e-06	2.28e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	1.9e-06	2.26e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—lung cancer	1.89e-06	2.26e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—lung cancer	1.87e-06	2.23e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—lung cancer	1.87e-06	2.22e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—EP300—lung cancer	1.86e-06	2.21e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—lung cancer	1.84e-06	2.19e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—POMC—lung cancer	1.83e-06	2.18e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT1—lung cancer	1.83e-06	2.17e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HRAS—lung cancer	1.79e-06	2.13e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HRAS—lung cancer	1.79e-06	2.13e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CREBBP—lung cancer	1.79e-06	2.13e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HRAS—lung cancer	1.76e-06	2.09e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL6—lung cancer	1.72e-06	2.04e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL6—lung cancer	1.71e-06	2.04e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CD—lung cancer	1.69e-06	2.02e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL6—lung cancer	1.68e-06	2e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ALB—lung cancer	1.67e-06	1.99e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTEN—lung cancer	1.65e-06	1.97e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKT1—lung cancer	1.62e-06	1.93e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKT1—lung cancer	1.58e-06	1.89e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT1—lung cancer	1.58e-06	1.88e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT1—lung cancer	1.58e-06	1.88e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—EP300—lung cancer	1.58e-06	1.88e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT1—lung cancer	1.55e-06	1.85e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—lung cancer	1.5e-06	1.78e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CB—lung cancer	1.48e-06	1.76e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—lung cancer	1.46e-06	1.74e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—lung cancer	1.46e-06	1.74e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—lung cancer	1.38e-06	1.64e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTEN—lung cancer	1.28e-06	1.52e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKT1—lung cancer	1.22e-06	1.46e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—EP300—lung cancer	1.22e-06	1.45e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKT1—lung cancer	1.19e-06	1.42e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—lung cancer	1.17e-06	1.39e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKT1—lung cancer	1.12e-06	1.34e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKT1—lung cancer	9.52e-07	1.13e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—lung cancer	9e-07	1.07e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKT1—lung cancer	7.35e-07	8.75e-06	CbGpPWpGaD
